# INTerpath-009 (NCT06623422)

> A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06623422
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed; Gemcitabine; Paclitaxel; Intismeran autogene; Placebo
- Enrollment: 680
- Primary outcome: Disease-Free Survival (DFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=interpath-009-nct06623422